ViroCell Biologics Retroviral & Lentiviral Vector CDMO
Home
Contact Us
Overview Innovation Research Viral vector design & optimization Viral Vector Process Development GMP lentiviral & retroviral vector manufacturing
Leadership Team Scientific Advisory Board Board of Directors
Careers
In the News Press Releases Conferences
Home What we do Overview Innovation Research Viral vector design & optimization Viral Vector Process Development GMP lentiviral & retroviral vector manufacturing Team ViroCell Leadership Team Scientific Advisory Board Board of Directors
ViroCell Biologics Retroviral & Lentiviral Vector CDMO
Manufacturing dreams Careers News In the News Press Releases Conferences Contact Us
Hired and retired: New appointments in the biopharma industry

Virocell Biologics: New COO.

READ MORE
Florence BuchananDecember 2, 2022CDMO, UK CDMO, ViroCell, gene therapy, cell and gene therapies, cell therapy, viral vector, viral vectors, New hires, Nick Maishman
LinkedIn0 0 Likes
Previous

Changing Faces: pharma supplier, DTx, and non-profit hires from November 2022

Florence BuchananDecember 16, 2022
Next

ViroCell strengthens senior management team with appointment of Nick Maishman as COO

In the NewsFlorence BuchananNovember 22, 2022viral vectors, UK CDMO, CDMO, gene therapy, cell therapy, clinical trials, cell and gene therapies, Nick Maishman, ViroCell, Pharmiweb.com
 

Team ViroCell is on the road

7-10 May – ISCT, International Society for Cell & Gene Therapy, New Orleans

13-17 May – ASGCT, New Orleans

2-4 Sept – Advanced Therapies Week Europe, Barcelona

23-26 Sept – CAR-TCR Summit US, Boston

 

If you’re looking for a lentiviral and retroviral vector CDMO, we’d love to connect

Get in touch
NewsroomCareersContact UsTerms of UsePrivacy Notice

London New York

 

©2025 ViroCell Biologics, Ltd. All rights reserved.